Figure 1.

Treatment pathways for early, high-risk TNBC, with adjuvant therapy options and the “high risk” definitions used in their respective pivotal trials highlighted in pink (olaparib), blue (capecitabine), or green (pembrolizumab). For TNBC, the neoadjuvant chemotherapy pathway is more frequently pursued within the current standards of care; surgery followed by adjuvant chemotherapy is a less common pathway (dotted line). BRCAm, BRCA-mutated; CbT-AC, carboplatin and paclitaxel/doxorubicin or epirubicin and cyclophosphamide; ER, estrogen receptor; gBRCAm, germline BRCA-mutated; LN, lymph node; NACT, neoadjuvant chemotherapy; pCR, pathological complete response; PR, progesterone receptor; Q3W, every 3 weeks. * If not done earlier.